From: The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma
 | Day 1 Pre-dose | Day 7 Pre-dose | Day 7 1 hr post-dose |
---|---|---|---|
GSK256066 (ppb) | 39.9 (31.0 to 51.3) | 34.7 (26.7 to 45.0) | 36.1 (28.1 to 46.3) |
Placebo (ppb) | 34.5 (24.6 to 48.4) | 33.1 (22.8 to 47.9) | 34.3 (23.2 to 50.6) |
Adjusted treatment ratio GSK256066 vs placebo | Â | 0.98 (0.85 to 1.31) | 1.03 (0.88 to 1.20) |